Regeneron Reports Third Quarter 2021 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Regeneron's (REGN) Antibody Cocktail Can Prevent Covid-19 Infection for 8 Months, Phase 3 Data Shows
November 8, 2021 8:30 AM ESTShares of Regeneron Pharmaceuticals (NASDAQ: REGN) are up 1.5% in pre-open Monday after the company announced new phase 3 trial results for its antibody cocktail against COVID-19 infections.
Data showed that risks of getting COVID-19 were slashed by 82% for up to eight months in patients that... More
Regeneron (REGN) Tops Q3 EPS by $6.15
November 4, 2021 6:37 AM EDTRegeneron (NASDAQ: REGN) reported Q3 EPS of $15.37, $6.15 better than the analyst estimate of $9.22. Revenue for the quarter came in at $3.45 billion versus the consensus estimate of $2.76 billion.
For earnings history and earnings-related data on Regeneron (REGN) click here.
... More